AU
UK
CA
NZ
IND
US
CureVac N.V. (Nasdaq: CVAC), a biotechnology company focused on mRNA-based medicines, announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for a Phase 1 clinical study of CVHNLC. This therapy is an mRNA-based precision immunotherapy designed …
Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a leader in satellite networking technology, announced that its defense division, Gilat Defense, has secured a contract to provide ongoing sustainment and support services for Satellite Transportable Terminal (STT) units deployed globally. These terminals are crucial …
Index Update
CXApp Inc. (NASDAQ: CXAI) has announced positive financial results for 2024, marking a successful transition to an AI-focused subscription application business. The company’s strategy of shifting to AI-driven products has resulted in notable improvements in its financial performance, customer retention, and operational efficiency.
Gold Resource (NYSE American: GORO) has announced positive results from its 2024 exploration drilling program at the Don David Gold Mine in Oaxaca, Mexico. The exploration focused on the Three Sisters and Gloria vein systems, revealing significant mineral discoveries. A total of 23 underground …
Lianhe Sowell International Group (NASDAQ: LHSW) made its Nasdaq debut on April 3, 2025, raising $8 million in gross proceeds. The company specializes in machine vision solutions, incorporating advanced technologies such as image processing, sound imaging, and video analysis. Lianhe Sowell's key innovations include …
Mesoblast (Nasdaq: MESO) has confirmed that its allogeneic cellular products, including Ryoncil® and Revascor®, will be exempt from U.S. tariffs. This exemption is made possible because the company’s products are designated as “U.S. Country of Origin” products. All products are manufactured using U.S. donors …
Telix Pharmaceuticals (ASX/NASDAQ: TLX) has appointed Anne Whitaker as a Non-Executive Director, effective April 7, 2025. Whitaker's appointment brings a wealth of knowledge and experience to the company, stemming from over three decades in the pharmaceutical, biotech, and specialty pharmaceutical sectors.
Index Update
Please wait processing your request...